Australian Researchers Develop Targeted Immunotherapy For Rare Blood Cancer

A team of Australian researchers has developed a promising new targeted therapy for myelofibrosis, a rare and serious form of blood cancer that disrupts the body’s ability to produce healthy blood cells.

The disease often leads to fatigue, pain, an enlarged spleen, and a diminished quality of life. Currently, treatments focus on symptom management rather than curing the disease.

The new research, published in the journal Blood, represents a shift towards targeting the abnormal blood cells that drive the disease using immunotherapy.

Prof Daniel Thomas, director of the South Australian Health and Medical Research Institute’s (SAHMRI) Blood Cancer programme, said that current therapies often control symptoms in people with myelofibrosis but do not selectively target the abnormal cells driving the disease.

He added, “Our research shows that by focusing on what makes these cells different, it may be possible to develop treatments that are both more effective and more targeted. This is part of a major paradigm shift in the treatment of myelofibrosis and related diseases.”

Using patient-derived cells, the team identified two key targets capable of selectively removing the disease-causing cells while sparing healthy ones.

This approach, known as precision immunology, harnesses the body’s immune system to recognise and act on abnormal cells with minimal impact on normal tissue.

The findings suggest that different biological forms of myelofibrosis may benefit from tailored targeted strategies, offering a more personalised approach to treatment.

Experts Highlight Broader Impact

Angel Lopez, Head of Human Immunology at SA Pathology, emphasised the significance of the research.

“The future of cancer treatment lies in understanding disease at a molecular and immune level and then translating that knowledge into therapies that are potent, long-lasting and precise,” he said.

While the study offers hope, experts caution that further research and clinical development are required before the therapy can be tested in patients.

Nevertheless, the findings represent a significant step forward in the search for more effective treatments for this challenging blood cancer.

This breakthrough highlights the growing potential of targeted immunotherapies in transforming cancer care, providing hope to patients with rare and difficult-to-treat conditions.